Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 EV-to-EBIT is 134.19 as of Aug. 09, 2026, which is 132% above its 10-year median of 57.86. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 684 Drug Manufacturers companies, Sai Parenteral's ranks worse than 95.03% on this metric.
The historical rank and industry rank for Sai Parenteral's's EV-to-EBIT or its related term are showing as below:
NSE:SAIPARENT'
s EV-to-EBIT Range Over the Past 10 Years
Min: 44.92 Med: 57.86 Max: 134.19
Current: 134.19
During the past 3 years, the highest EV-to-EBIT of Sai Parenteral's was 134.19. The lowest was 44.92. And the median was 57.86.
NSE:SAIPARENT's EV-to-EBIT is ranked worse than 95.03% of 684
companies
in the Drug Manufacturers industry
Industry Median: 15.69
vs NSE:SAIPARENT: 134.19
Sai Parenteral's (NSE:SAIPARENT) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sai Parenteral's's Enterprise Value for the quarter that ended in Sep. 2025 was ₹0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹201 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's EV-to-EBIT Related Terms
Sai Parenteral's EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's EV-to-EBIT Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
EV-to-EBIT
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
EV-to-EBIT
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's EV-to-EBIT falls into.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was ₹201 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a EV-to-EBIT of 134.19 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sai Parenteral's and its competitors. This is 132% above median its historical median of 57.86. Over the past decade, Sai Parenteral's' EV-to-EBIT has ranged from 44.92 to 134.19. According to the industry distribution chart, Sai Parenteral's ranks #650 out of 684 companies in the Drug Manufacturers industry, placing it in the top 95%.
Is Sai Parenteral's' EV-to-EBIT too high?
Sai Parenteral's' current EV-to-EBIT of 134.19 is 132% above median its 10-year median of 57.86. Over the past 10 years, this metric has ranged from a low of 44.92 to a high of 134.19. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Sai Parenteral's' value of 134.19 is 755.3% above this industry median. Based on the distribution chart, Sai Parenteral's ranks #650 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #650 out of 684 companies for EV-to-EBIT. This places Sai Parenteral's in the lower half of its industry. The industry median EV-to-EBIT is 15.69. Sai Parenteral's' value of 134.19 is 755.3% above this benchmark. Historically, Sai Parenteral's' own EV-to-EBIT has ranged from 44.92 to 134.19 over the past decade. While the company's 10-year median is 57.86 vs. the industry median of 15.69, Sai Parenteral's has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current EV-to-EBIT of 134.19 is 755.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current EV-to-EBIT is 134.19, which is 132% above median its own 10-year median of 57.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current EV-to-EBIT of 134.19. The current EV-to-EBIT is 134.19, which is 132% above median its 10-year median of 57.86 and 755.3% above the Drug Manufacturers industry median of 15.69. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current EV-to-EBIT is 134.19 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
